We are driven to make a difference for patients and those who care for them.

At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.

We are pioneering a new field of medicine focused on controlling  gene expression . The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has potential to provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.

We are advancing two clinical-stage drug candidates, tamibarotene and SY-2101, across three genomically defined patient populations in higher-risk myelodysplastic syndrome (HR-MDS), acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).

In addition, we seek partnerships that maximize value for our partners and us. We are exploring partnerships for our SY-5609 clinical program, an oral reversible CDK7 with best-in-class selectivity and potency, enabling broad development potential. We are also exploring partnerships for our preclinical oncology programs.

We invite you to learn more about our programs and ongoing clinical trials, as well as to explore a select list of resources for these diseases.

Nancy Simonian, M.D.
Chief Executive Officer of Syros

Nancy Simonian, M.D.
Chief Executive Officer of Syros